8-K Announcements
6Material company update
Jun 12, 2026·SEC
Material company update
May 8, 2026·SEC
Material company update
Mar 24, 2026·SEC
BioAge Labs, Inc.(BIOA)Earnings, Financials & Key Ratios
BIOA•NASDAQ
$23.76
Price updated Jun 27, 2026
AboutBioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.Show more
- Revenue$9M
- EBITDA-$93M-18.6%
- Net Income-$81M-13.4%
- EPS (Diluted)-2.24-13.1%
- Gross Margin100%
- EBITDA Margin-1029.09%
- Operating Margin-1031.46%
- Net Margin-896.11%
- ROE-27.09%+71.5%
BIOA Price & Volume
BioAge Labs, Inc. (BIOA) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Milestone Revenue Growth
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial Position:Adequate
Cash Flow:Burning
Primary Risk:Clinical Trial Execution Risk
"BioAge Labs remains a pre-commercial biotechnology entity whose valuation is entirely dependent on the successful advancement of its azelaprag clinical program. While the company has successfully bolstered its equity base to $379.1 million as of 2026Q1, it continues to face significant operational losses, with quarterly R&D expenditures reaching $24.5 million in 2025Q4. Investors should monitor the company's ability to convert its current $241.8 million cash position into meaningful clinical milestones before further dilution becomes necessary."
Verdict Logic
while the company holds a significant $241.8 million cash reserve to fund operations, the lack of commercial revenue and the $355.7 million accumulated deficit suggest high execution risk for long-term investors.
BIOA Growth Metrics
BioAge Labs, Inc. (BIOA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM610.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-26.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-18.23%
Return on Capital
10 Years-86.74%
5 Years-86.74%
3 Years-41.55%
Last Year-30.66%
BIOA Recent Earnings
BioAge Labs, Inc. (BIOA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (63%)●Beat Revenue 6/12 qtrs (100%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.52+18.7%
$0.64
Rev
$3M+155.9%
$1M
Q2 2026
May 5, 2026Metric
Actual
Est
EPS
$0.52+18.7%
$0.64
Rev
$3M+155.9%
$1M
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$0.72+13.3%
$0.83
Rev
$3M+119.9%
$1M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.56+16.4%
$0.67
Rev
$2M+80.2%
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.52vs $0.64+18.7% | $3Mvs $1M+155.9% |
| Q2 2026 | May 5, 2026 | $0.52vs $0.64+18.7% | $3Mvs $1M+155.9% |
| Q2 2026 | Mar 24, 2026 | $0.72vs $0.83+13.3% | $3Mvs $1M+119.9% |
| Q4 2025 | Nov 6, 2025 | $0.56vs $0.67+16.4% | $2Mvs $1M+80.2% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for BioAge Labs, Inc. (BIOA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $23.76 | $894.56M | -10.61 | — | -896.11% | -27.09% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $182.08 | $38.71B | -30.60 | — | — | -83.22% | — | |
| $109.80 | $7.15B | 32.20 | 0.5% | 18.05% | 24.33% | — | |
| $109.84 | $7.53B | -35.32 | 45.83% | -93.84% | -204.35% | — | |
| $6.01 | $355.24M | -1.61 | 8.72% | -109.99% | -61.41% | — |
Compare BIOA vs Peers
BioAge Labs, Inc. (BIOA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BIOA SEC Filings & Documents
BioAge Labs, Inc. (BIOA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BIOA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BIOA Frequently Asked Questions
BioAge Labs, Inc. (BIOA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is BioAge Labs, Inc.'s revenue?
BioAge Labs, Inc. (BIOA) reported $10.3M in revenue for fiscal year 2025.
Is BIOA profitable?
BioAge Labs, Inc. (BIOA) reported a net loss of $89.9M for fiscal year 2025.
Dividend & Returns
What is BIOA's return on equity?
BioAge Labs, Inc. (BIOA) has a return on equity (ROE) of -27.1%. Negative ROE indicates the company is unprofitable.
What is BioAge Labs, Inc.'s free cash flow?
BioAge Labs, Inc. (BIOA) had negative free cash flow of $88.6M in fiscal year 2025, likely due to heavy capital investments.